FOLD (Amicus Corp) Earnings growth in current year

The orphan drug status of Amicus Therapeutics (FOLD) ensures high margins and stable cash flow. John Crowley's effective leadership optimizes regulatory engagement, while advanced outsourcing scales production. The comparable year-over-year growth rate of earnings per share confirms these successes, while 613.70 captures the current value of the indicator, smoothing out market noise.

FOLD: Amicus Therapeutics Earnings per share growth in current year 07/04/2022 - 05/09/2026

Financial and market metric breakdowns for Amicus Therapeutics (FOLD)

- share price and expert price forecast:

Price Amicus Therapeutics Inc|FOLD - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Amicus Corp|FOLD - Enterprise Value

- book capitalization data:

Net Assets per Single Share Amicus Therapeutics|FOLD - Company Book Value|Market-to-Book Ratio amicusrx.com|FOLD - Aggregate Company Assets

- debt burden and liquidity indicators:

- earnings and valuation multiples information:

FOLD - Company Net Income|Future Profit Amicus Therapeutics|FOLD - P/E Multiple|Market Cap to Projected Earnings Amicus Corp|FOLD - PEG Multiple|Enterprise Value to EBITDA Ratio Amicus Corp|FOLD - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Amicus Therapeutics|FOLD - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months amicusrx.com|FOLD - Net earnings per share growth this year|Expected earnings per share trend next year Amicus Therapeutics

- revenue and sales proceeds data:

FOLD - Company Sales|Company Projected Revenue Volume Amicus Therapeutics Inc|FOLD - P/S Multiple|Forward Price to Sales Amicus Corp

Basic company analysis:FOLD - Amicus Therapeutics Inc

Finished products of Amicus Therapeutics, Inc.

This metric reflects capital density dynamics through the percentage change in net income per share compared to last year. By analyzing the relative change in EPS versus the same period last year, an investor assesses the efficiency of value generation, which at Amicus Therapeutics (FOLD) is supported by the implementation of ESG standards and the optimization of laboratory costs that reduce operational risks during therapy development.

Main competitors